Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. Longo DL, editor. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, OCN, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749.
   PubMed Web of Science ®Google Scholar
• Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization: Unfolding and Mislocalization of NPM1 Mutants in AML. Protein Sci. 2013;22(5):545–556.
   PubMed Web of Science ®Google Scholar
• Heath EM, Chan SM, Minden MD, et al. Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 2017;31(4):798–807.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Ivey A, Huntly BJP. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.
   PubMed Web of Science ®Google Scholar
• Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103–1108.
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199.
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Eisfeld A-K, Nicolet D, et al. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol. 2016;175(2):226–236.
   PubMed Web of Science ®Google Scholar
• Ok CY, Loghavi S, Sui D, et al. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019;104(2):305–311.
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433.
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia: 2016 update on risk-stratification and management: acute myeloid leukemia. Am J Hematol. 2016;91(8):824–846.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Richards S, Aziz N, Bale S, ACMG Laboratory Quality Assurance Committee, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424.
   PubMed Web of Science ®Google Scholar
• Carbonell D, Suárez-González J, Chicano M, et al. Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. Cancers. 2019;11(9):1364.
   PubMed Web of Science ®Google Scholar
• R Development Core Team. R: A language and environment for statistical computing. [Internet]. R Foundation for Statistical Computing, Vienna, Austria.; 2008. Available from: http://www.R-project.org.
   Google Scholar
• Patel JL, Schumacher JA, Frizzell K, et al. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia. Leuk Res. 2017;56:7–12.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Strickland SA, Shaver AC, Byrne M, et al. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leuk Res. 2018;65:67–73.
   PubMed Web of Science ®Google Scholar
• Herold T, Rothenberg-Thurley M, Grunwald VV, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia [Internet]. 2020. [cited 2020 Oct 28]; Available from: http://www.nature.com/articles/s41375-020-0806-0.
   Google Scholar
• Martignoles J-A, Delhommeau F, Hirsch P. Genetic hierarchy of acute myeloid leukemia: from clonal hematopoiesis to molecular residual disease. IJMS. 2018;19(12):3850.
   Google Scholar
• Patel SS, Kuo FC, Gibson CJ, et al. High NPM1 -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816–2825.
   PubMed Web of Science ®Google Scholar
• Patel SS, Pinkus GS, Ritterhouse LL, et al. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo AML. Am J Hematol. 2019;94(8):921–928. [cited 2019 Jun 26]; Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25544.
   PubMed Web of Science ®Google Scholar
• Zhang S, Qin F, Yang L, et al. Nucleophosmin mutations induce chemosensitivity in THP-1 leukemia cells by suppressing NF-κB activity and regulating Bax/Bcl-2 expression. J Cancer. 2016;7(15):2270–2279.
   PubMed Web of Science ®Google Scholar
• Khan I, Halasi M, Zia MF, et al. Nuclear FOXM1 drives chemoresistance in AML. Leukemia. 2017;31(1):251–255.
   PubMed Web of Science ®Google Scholar
• Russ AC, Sander S, Luck SC, et al. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. Haematologica. 2011;96(12):1783–1791.
   PubMed Web of Science ®Google Scholar
• Corces-Zimmerman MR, Hong W-J, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111(7):2548–2553.
   PubMed Web of Science ®Google Scholar
• Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811–822.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood. 2008;111(5):2527–2537.
   PubMed Web of Science ®Google Scholar
• Perry M, Bertoli S, Rocher C, et al. FLT3-TKD mutations associated with NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(12):e545–e550.
   PubMed Web of Science ®Google Scholar
• Boddu P, Kantarjian H, Borthakur G, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1(19):1546–1550.
   PubMed Web of Science ®Google Scholar
• Moreno I, Martín G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88:19–24.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Weber D, Paschka P, et al.; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32(1):30–37.
   PubMed Web of Science ®Google Scholar
• Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget [Internet]. 2015;6(39):42345–42353. [cited 2019 Jul 1]. Available from: http://www.oncotarget.com/fulltext/5645.
   PubMedGoogle Scholar
• Ferret Y, Boissel N, Helevaut N, et al. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica. 2018;103(5):822–829.
   PubMed Web of Science ®Google Scholar
• Forghieri F, Comoli P, Marasca R, et al. Minimal/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: a clinical viewpoint and perspectives. IJMS. 2018;19(11):3492.
   Google Scholar
• Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Ther Adv Hematol. 2017;8(9):245–261.
   PubMed Web of Science ®Google Scholar
• Bacher U, Porret N, Joncourt R, et al. Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia. Haematologica. 2018;103(10):e486–e488.
   PubMed Web of Science ®Google Scholar
• Luskin MR, Stone RM. Can minimal residual disease determination in acute myeloid leukemia be used in clinical practice? J Oncol Pract. 2017;13(8):471–480.
   PubMed Web of Science ®Google Scholar